HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: Belinostat is a novel histone deacetylase (HDAC) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of relapsed peripheral T-cell lymphoma (PTCL).